ArticleMolecular genetics and genomics : MGG2026
Immunoinformatics-guided design of a multi-epitope vaccine targeting the envelopment polyprotein of oropouche virus.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Structure-Guided Immunoinformatics for the Rational Design of a Multi-Epitope Vaccine Against Batai Orthobunyavirus.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Integrative immunoinformatics and structural modeling for the rational design of a multi-epitope vaccine candidate against human cytomegalovirus.Scientific reports · 2026Article
- Integrative 16S rRNA characterization, pan-genome, and immunoinformatics approaches for the design of a multi-epitope vaccine against Bacillus cereus, a foodborne pathogen.World journal of microbiology & biotechnology · 2026Article
- Immunoinformatics based design of a multiepitope vaccine targetingOpen medicine (Warsaw, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Oropouche virus is an emerging and neglected arbovirus of growing public health concern in Latin America, with recent epidemiological surveillance reporting 832 confirmed cases in 2023 and 5,913 cases during early 2024 in Brazil, predominantly in the Amazon region. Despite its increasing spread, no licensed vaccines or antiviral therapies are currently available. In this study, we aimed to design and computationally evaluate a multi-epitope vaccine candidate targeting the OROV envelopment polyprotein using integrated immunoinformatics, molecular modeling, and immune simulation approaches. The complete polyprotein sequence was analyzed to identify antigenic, non-allergenic, and non-toxic cytotoxic and helper T-cell epitopes. Selected epitopes were assembled into a chimeric construct incorporating an adjuvant, suitable linkers, and a PADRE sequence to enhance immune recognition. Physicochemical properties, tertiary structure, receptor binding, dynamic stability, and immune response potential were comprehensively evaluated in silico. The final vaccine construct comprised 241 amino acids and demonstrated favorable stability with instability index score of 24.95, hydrophilicity with GRAVY score of - 0.241, and with an estimated global population coverage of 94.07%. Molecular docking revealed favourable binding affinity to TLR4 with a binding energy of - 1067.1, while molecular dynamics simulations showed structural stability, with an average RMSD of 0.40 nm and limited fluctuations. Immune simulations predicted rapid antigen clearance, robust Th1-polarized responses characterized by strong IFN-γ and IL-2 production, sustained IgG responses, and expansion of memory B and T cells. Overall, these findings indicate that the proposed multi-epitope vaccine construct is stable, immunogenic, and capable of inducing broad immune responses, providing a strong rationale for experimental validation and future vaccine development against Oropouche virus.
Indexed as
Identifiers
41706189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.